The new superbug Neisseria gonorrhoeae has retained resistance to antimicrobials previously recommended for first-line treatment and has now demonstrated its capacity to develop resistance to the extended-spectrum cephalosporin, ceftriaxone, the last remaining option for first-line empiric treatment of gonorrhea. An era of untreatable gonorrhea may be approaching, which represents an exceedingly serious public health problem. Herein, we review the evolution, origin and spread of antimicrobial resistance and resistance determinants (with a focus on extendedspectrum cephalosporins) in N. gonorrhoeae, detail the current situation regarding verified treatment failures with extended-spectrum cephalosporins and future treatment options, and highlight essential actions to meet the large public health challenge that arises with the possible emergence of untreatable gonorrhea. Essential actions include: implementing action/response plans globally and nationally; enhancing surveillance of gonococcal antimicrobial resistance, treatment failures and antimicrobial use/misuse; and improving prevention, early diagnosis and treatment of gonorrhea. Novel treatment strategies, antimicrobials (or other compounds) and, ideally, a vaccine must be developed. Keywords action plan; antimicrobial resistance; cefixime; ceftriaxone; cephalosporins; Neisseria gonorrhoeae; penA; surveillance; treatment failure
than the transiently acquired gonococcus. Thus, resistance may initially emerge in commensal Neisseria spp., which act as a reservoir of AMR genes that can be readily transferred to gonococci through transformation, particularly in pharyngeal gonorrhea [1, 17, [34] [35] [36] . Pharyngeal gonorrhea is mostly asymptomatic, and gonococci and commensal Neisseria spp. can coexist for extended time periods in the pharynx and share genetic material. Once AMR determinants are acquired by N. gonorrhoeae, efficient intraspecies transfer between gonococcal strains, via transformation, can spread these determinants rapidly throughout the population. Horizontal gene transfer has likely played a pivotal role in the spread of penA mosaic alleles, resulting in decreased susceptibility/resistance to ESCs [23, 25, 37] .
Acquired AMR determinants are stably maintained in the gonococcal population many decades after withdrawal of the specific antimicrobials from treatment regimens [1, 17, 38] . This persistence and selection of AMR-resistant clones may be as a result of maintained selective pressure in the community due to antimicrobials being used/misused to treat other bacterial infections. However, the persistence may also be because the AMR determinants: do not significantly affect biological fitness; lower the fitness, although this is compensated by having a stabilizing second-site mutation(s); or even enhance the fitness and make the AMR clones more successful in transmission and virulence [17, 38] . For example, gonococci lacking a functional MtrC-MtrD-MtrE multidrug-resistance efflux pump (a pump that expels multiple antimicrobials and host-derived compounds from the cell) or MtrA (an activator of mtrCDE transcription) had decreased fitness in murine competition experiments, whereas gonococci lacking MtrR (a repressor of mtrCDE transcription) had increased fitness compared with wild-type gonococci [39] [40] [41] . Interestingly, a spontaneous compensatory inhost mutation in the mtrR locus of an mtrA mutant restored fitness to wild-type levels [40] .
MtrR can regulate the expression of nearly 70 gonococcal genes and, accordingly, this repressor may also be important for processes involved in basic metabolism, adaptation, biological fitness and pathogenicity [42] . Similarly, gyrA91/95 mutations (encoding an altered GyrA subunit of DNA gyrase), which cause decreased susceptibility/resistance to ciprofloxacin, increased fitness compared with wild-type gonococci in the same murine model. Inclusion of an additional parC86 mutation (encoding an altered ParC subunit of topoisomerase IV), which further increases ciprofloxacin resistance, abrogated this fitness advantage, but compensatory mutations could be isolated that restored in vivo fitness [43] .
These examples demonstrate how AMR mechanisms can increase bacterial survival and fitness, and suggest why AMR mechanisms are maintained despite discontinuation of specific antimicrobials in treatment regimens. Thus, highly successful gonococcal clones have acquired additional virulence determinants/enhanced biological fitness that allow them to evade or render ineffective mucosal host defenses and spread widely to predominate in local populations, with subsequent emergence in national and even international populations. Attributes that determine success may or may not be affected by AMR determinants [1, 44] , but when one of these successful clones acquires AMR determinants for the antimicrobials used for treatment and is subsequently introduced to a high-frequency transmitting population, resistance spreads quickly and widely, and these clones can represent a large fraction of the gonococcal population [1, 45, 46] .
Historically, most gonococcal AMR appears to have originated in the WHO Western Pacific Region (WPR). For example, β-lactamase-mediated penicillin resistance, spectinomycin resistance and fluoroquinolone resistance (with the latter being a well-documented example), all appear to have originated and demonstrated high resistance prevalence in the WHO WPR and subsequently spread worldwide, clearly illustrating that gonococcal AMR is a global concern [1, 17, 23, 25, 47] . The first cases and/or outbreaks were identified in this region and, particularly, resistance prevalence was high prior to mainly any resistance being detected in other settings. These observations suggest that resistance emerged in the WHO WPR and, subsequently, spread via sex tourists, long-distance truck drivers and forced migration, to the Pacific Rim countries within the WHO WPR, the USA, southeast and central Asia, and Europe. To provide an evidence-basis for this hypothesis, it would be valuable to model the emergence and spread of gonococcal AMR with an international perspective; however, sufficient quality-assured geographical and temporal metadata (regarding gonorrhoea patients, their sexual networks and the gonococcal population, including its AMR and additional phenotypic and genetic characteristics) are lacking in most settings worldwide. The reasons for emergence of AMR in the WHO WPR can only be hypothesized, but likely factors include extensive use and particularly misuse of antimicrobials in general, which results in AMR emergence in many bacterial species, including N. gonorrhoeae, and in the treatment of gonorrhea itself. This misuse is catalyzed by the unrestricted access to a huge variety of antimicrobials with consequent inappropriate selection, overuse and, in some settings, the use of generic antimicrobials of suboptimal quality and/or dose. This lack of optimal antimicrobial selection and use (in general and for gonorrhea) is presumably due to deficient monitoring of AMR in vitro, clinical failures, antimicrobial use and clinical efficacy of antimicrobials. Of particular concern, is that in regions with a high incidence of gonorrhea and ineffective disease control measures to decrease the gonorrhea burden, resistance can spread rapidly, nationally and internationally [1] .
Emergence and spread of in vitro & in vivo decreased susceptibility/resistance to ESCs
Over the past decade, strains of N. gonorrhoeae with decreased susceptibility/resistance to ESCs appear to have emerged in Japan and spread internationally. In the 1990s through to the early 2000s, ceftriaxone was not permitted for treatment of gonorrhea in Japan. Therefore, a variety of oral ESCs, many comprising suboptimal efficacy, and dose regimens were used in monotherapy (if resistance was indicated, cefodizime or spectinomycin was used) [48, 49] . Longer, multiple low-dose regimens of oral cephalosporins were commonly utilized. Some of these regimens resulted in ESC concentrations that were subinhibitory, which may thereby have selected for resistant clones [21, [49] [50] [51] . In many settings worldwide, only the most potent oral ESC, cefixime (in optimized 400 mg × 1 dose), has been used for treatment. However, when applied, single dose cefixime therapy in Japan included only 300 mg as a standard dose [52] . Thus, between 1995 and 2000, in Fukuoka, Japan, the MIC peak of cefixime and ceftriaxone in gonococcal isolates increased from 0.008 μg/ml to 0.25 μg/ml, and from 0.015 μg/ml to 0.064 μg/ml, respectively [49] . Furthermore, in six hospitals in central Japan between 1999 and 2002, the proportion of gonococcal isolates with decreased susceptibility/resistance to cefixime (MIC ≥0.5 μg/ml) and ceftriaxone (MIC ≥0.5 μg/ml) increased, from 0 to 30.2% and from 0 to 0.9%, respectively [50] . From 1999 to 2001, eight treatment failures with cefixime (200 mg orally × 2; 6 h apart) were reported and isolates cultured from these patients had cefixime MICs of 0.125-0.25 μg/ml [21] . In 2002-2003, four treatment failures with an extended cefixime regimen (200 mg orally twice a day for 3 days) were documented [30] . Isolates obtained from these treatment failures exhibited substantially elevated MICs of cefixime (0.5-1 μg/ ml) and ceftriaxone (0.125-0.5 μg/ml). In 2006, all oral ESCs were excluded from treatment guidelines in Japan.
The theory that gonococcal strains with decreased susceptibility/resistance to ESCs, particularly oral ESCs, have spread internationally from Japan is in concordance with decreased in vitro susceptibility to cefixime and ceftriaxone in WHO WPR countries, including Australia, China, Hong Kong, Taiwan, USA, Canada, South America, southeast Asia, the EEA and Russia, identified in subsequent years [1, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] 23, 25, 32, 33, 45, 47, 51, [53] [54] [55] [56] [57] [58] 205] . For example, from 2009 to 2010, decreased susceptibility/resistance to cefixime in EU/EEA gonococcal isolates increased from 4 to 9%, and this resistance phenotype was detected in 17 countries [203, 205] . Worryingly, gonococcal AMR surveillance remains sporadic, limited or even lacking in many regions worldwide, including Eastern Europe, Central Asia, Africa, and large parts of South America and the Caribbean [1, 12, 20, [59] [60] [61] ; these regions also suffer from a high burden of gonorrhea [59, 60, 201] . Accordingly, the global burden of decreased susceptibility/resistance to ESCs is unknown.
It is of concern that the first treatment failures with cefixime outside Japan [22, [25] [26] [27] In 2010, the first verified cefixime treatment failures beyond Japan were reported in Norway [27] and, subsequently, verified failures were documented in the UK [22] , Austria [26] and France [25] . The main characteristics of all microbiologically verified failures are described in Table 1 . Briefly, the cefixime MICs of the gonococcal isolates resulting in treatment failure were 0.25-4 μg/ml and the country of infection varied widely. Nevertheless, all genetically typed isolates belonged to either the multilocus sequence typing (MLST) ST1901 and N. gonorrhoeae multiantigen sequence typing (NG-MAST) ST1407 or genetically closely related NG-MAST STs, such as ST3779 and ST3431 (Table 1) [22, [25] [26] [27] . Disquietingly, the strain (referred to as F89) resulting in cefixime failure in a man who has sex with men (MSM) in Quimper, France [25], appears to represent a subclone of the MLST ST1901/NG-MAST ST1407 clone that has developed high-level resistance to cefixime (MIC = 4 μg/ml) and ceftriaxone (MIC = 1-2 μg/ml). F89 was the second identified XDR [1] gonococcal strain [25] . A genetically and phenotypically similar ceftriaxone-resistant strain has subsequently been described in Spain, causing gonorrhea in two MSMs with sexual contact [31] . This report illustrates that this ceftriaxone-resistant strain can spread and, accordingly, does not have a deleteriously low biological fitness.
Ceftriaxone treatment failures
Five failures in treating pharyngeal gonorrhea with ceftriaxone, the last remaining treatment option, have been verified in Australia (n = 2) [29] , Sweden (n = 1) [24] , Slovenia (n = 1) [28] , and Japan (n = 1) [23] . The Swedish [24] and Slovenian [28] treatment failures were caused by the MLST ST1901/NG-MAST ST1407 clone. The main characteristics of these failures are described in Table 2 . The relatively low MICs of the gonococcal strains (with exception of the one in Japan) causing these failures, especially those from Australia that had near wild-type MICs (Table 2) , likely reflecting the difficulty in treating pharyngeal gonorrhea compared with urogenital infections [1, 3, 14, 19, 20, [62] [63] [64] . Thus, it appears likely that treatment failures with ceftriaxone will initially arise from pharyngeal gonorrhea. Unfortunately, the failure to treat pharyngeal gonorrhea in a female sex worker with ceftriaxone 1 g × 1 in Kyoto, Japan, was caused by the first ever XDR [1] N. gonorrhoeae strain ('H041'; the first gonococcal 'superbug'), which displayed high-level resistance to cefixime (MIC = 8 μg/ml) and ceftriaxone (MIC = 2-4 μg/ml), and to most other antimicrobials tested (n = 28) [23] . Ceftriaxone treatment (1 g × 1) results in a median time of free ceftriaxone above the MIC of only 6.0 h and 0 h for the detected MICs of 2 μg/ml (agar dilution method) and 4 μg/ml (Etest®), respectively [51] . Consequently, even with this treatment, H041 will escape eradication in almost any patient. H041 was assigned to MLST ST7363 and the novel NG-MAST ST4220 (Table 2 ). H041 may of accordingly represent a subclone of the successful cefixime-resistant MLST ST7363, which has been prevalent in Japan, that has also developed high-level ceftriaxone resistance [23, 37, 65] .
International spread of successful gonococcal clones causing treatment failures with ESCs
The gonococcal clones MLST ST1901 (commonly NG-MAST ST1407) and MLST ST7363, both of which likely originated in Japan [23, 25] , were responsible for all of the verified cefixime treatment failures and at least three of the five ceftriaxone treatment failures (Tables 1 & 2) ; both of these clones are spreading worldwide [6, 8, 22, 23, [25] [26] [27] [28] 37, 55, [65] [66] [67] [68] [69] [70] [71] [72] [73] . During the early 2000s, MLST ST1901 (frequently NG-MAST ST1407 in many countries) started to replace MLST ST7363 as the most predominant MLST ST in Japan, and it is currently responsible for most of the decreased susceptibility/resistance to ESCs in Europe [6, 8, 23, 25, 65] . Nevertheless, although NG-MAST ST1407 is the most prevalent ST of MLST ST1901 in Europe, many NG-MAST STs of this MLST clone have been identified globally, particularly in Japan, where the MLST ST1901 clone has been spreading for many years [6,8,22, 
Verification of treatment failures
It is crucial to survey for and appropriately verify as well as follow-up treatment failures with ESCs [1, [202] [203] [204] 207] . Recent WHO publications [1, 202, 207] have described in detail important laboratory parameters to verify a treatment failure, which ideally requires assessing pre-and post-treatment isolates for MICs, genotype, and genetic resistance determinants. Additionally, a detailed clinical history that excludes reinfection and records the treatment regimen used is mandatory. The correlates between genetic resistance determinants, ESC MICs, and treatment outcome remain weak. It is crucial to examine all gonococcal strains causing treatment failure as well as isolates showing high-level ESC resistance in vitro, including determination of resistance determinants. This is essential to establish appropriate MIC breakpoints for ESC resistance (together with pharmacokinetic/ pharmacodynamic simulations), to develop genetic methods for screening to identify specific ESC-resistant clones and, ideally, to carry out genetic ESC resistance (and AMR in general) testing.
Decreased susceptibility/resistance to ESCs: genetic resistance determinants Acquisition of resistance determinants from a resistant strain to a susceptible strain can be achieved in the laboratory by step-wise transformation. Many studies have investigated the steps of transformation for penicillin and ESC resistance, and these reveal a complex and multifaceted interaction of at least four known resistance determinants (Figure 1 ): penA, encoding altered forms of PBP2, the lethal target for β-lactam antibiotics; mtrR, resulting in overexpression of the MtrC-MtrD-MtrE efflux pump; penB, encoding mutations in the major outer membrane porin; and ponA, encoding an altered form of PBP1. These and other determinants are discussed in more detail below.
Alteration of PBP2, the lethal target for ESCs
The first step in decreased susceptibility/resistance to ESCs is alteration of the penA gene encoding the transpeptidase PBP2 (Figure 2) , the lethal target for ESCs and other β-lactam antibiotics. Acquisition of penA mosaic alleles, and non-mosaic penA alleles with mutations at A501, are associated with enhanced ESC MICs [8, [23] [24] [25] [26] [27] [28] 31, 36, 37, 52, 68, 69, [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] . The mosaic penA alleles appear to have evolved by DNA uptake and subsequent recombination of partial penA genes from commensal Neisseria spp. commonly residing in the oropharynx (i.e., Neisseria sicca, Neisseria perflava, Neisseria cinerea, Neisseria polysaccharea and/or Neisseria flavescens) into the gonococcal penA gene [36, 75, 76, 79] . Pharyngeal gonorrhea may have provided the means for this in vivo intrageneric horizontal transfer [1, [34] [35] [36] . The relative increases in MICs due to acquisition of a penA mosaic allele appear to be higher for cefixime than for ceftriaxone [23, 25, 86] , which may be due to structure/activity relationships associated with the longer side chain at the C-3 position of the cephem skeleton of ceftriaxone [1, [78] [79] [80] 87] . and V316T, were responsible for the ESC resistance (by altering the β-lactam binding pocket) [79] , especially to cefixime [80] . However, it was subsequently shown that while reversion of these three amino acids to wild-type dramatically decreased ESC resistance, introduction of these same amino acids into the wild-type PBP2 sequence had little to no effect on resistance. These data suggest that the three mutations only increase resistance in the presence of other mutations in the penA mosaic alleles that have little or no apparent effect on their own [81], a phenomenon known as epistasis. Inspection of the crystal structure of PBP2 reveals that the G545S mutation is present at the beginning of the a11 helix, one of the two helices on top of the five anti-parallel β-strands typical of β-lactaminteracting proteins. The main chain amides of G545 and G546 are within hydrogen-bonding distance of the side chain hydroxyls of Thr498 and Thr500, respectively, located within the KTG(T) active site motif ( Figure 3a) . The main chain amide of Thr500 is predicted to form the oxyanion hole for stabilization of the transition state and, thus, one effect of the G545S mutation might be to lower acylation by compromising the geometry of the transition state/ tetrahedral intermediate. Alternatively, the hydroxyl side chains of Thr498 and Thr500 may interact with the β-lactam carboxylate in the covalent complex, and alteration of these contacts may also lower the acylation [81]. Ile312 and Val316 are located on the opposite side of Ser310 and Lys313 of the SxxK active site motif on the α2 helix and pack into a hydrophobic pocket (Figure 3b ). Mutation to larger (I312M) or more hydrophilic (V316T) side chains might disrupt these interactions and alter the position of the SxxK active site motif, which would also result in decreased acylation [81] . Tomberg et al. also verified that an additional mutation, N512Y, contributes to decreased susceptibility/resistance to ESCs (without affecting penicillin susceptibility), although it plays a lesser role than the three alterations discussed above. N512 is relatively distant from the active site (Figure 3b ) on the β3-β4 loop, and it is possible that the N512Y alteration perturbs the architecture of the KTG active site motif of the β3 strand [81].
Characterization of the novel penA mosaic allele in the first described XDR [1] strain, H041, with high-level resistance to cefixime (MIC = 8 μg/ml) and ceftriaxone (MIC = 2-4 μg/ml), revealed 12 additional amino acid alterations compared with penA mosaic allele X, which has been associated with cefixime treatment failures in Japan [23] . Transformation experiments using full-length and partial penA H041 mosaic alleles indicated that the novel A311V and T316S alterations may contribute to high-level ESC resistance, due to the proximity to the β-lactam active site in PBP2 (Figure 3b ) [23] . However, the full cause of ESC resistance in H041 needs to be appropriately elucidated, which is in progress.
A single amino acid alteration at position A501 (mostly A501V, but sometimes A501T) in PBP2, which until recently was found mainly in non-mosaic penA alleles, is associated with decreased susceptibility/resistance to ESCs, particularly ceftriaxone [8, 25, 31, 52, 68, 69, 74, 77, 80, 81, [83] [84] [85] . The rarity of strains containing a penA mosaic allele with an A501 mutation may suggest that these strains have a lower biological fitness [25, 81] , although this has not been formally investigated. A501 alterations could be gonococcal-specific, as they have not yet been reported in any other Neisseria species, suggesting that they may have evolved and been selected in gonococci through spontaneous mutation and selective pressure with ESCs instead of by transformation from another species [8, 25, 81, 85] . In support of this hypothesis, the isolation of a spontaneous A501V mutation during transformation experiments with mosaic penA alleles has been reported [80] . Given the concern that A501 mutations might emerge in mosaic penA alleles, Tomberg et al. examined the effects of introducing an A501V mutation into a mosaic penA allele and transforming it into both a penicillin-susceptible and a penicillin-resistant gonococcal strain. Introduction of the A501V mutation increased the MIC of both cefixime and ceftriaxone by two-to three-fold, while the penicillin MIC decreased [81] . As originally feared, a strain containing a traditional penA mosaic allele with an A501 mutation was reported only a year later [25] . This strain (F89), which contained a penA mosaic allele XXXIV with an additional A501P alteration, was the second XDR [1] strain identified and displayed highlevel resistance to cefixime (MIC = 4 μg/ml) and ceftriaxone (MIC = 1-2 μg/ml). Transformation experiments confirmed that this novel penA mosaic allele was responsible for the high-level ESC resistance [25] . Isolates harboring the penA mosaic allele XXXIV, which commonly belong to the successful MLST ST1901/NG-MAST ST1407 clone, have been reported in many countries worldwide [25, 28, 55, [67] [68] [69] 71, 73, 74] , and it is of major concern that an A501P (or similar) alteration will emerge in additional strains containing the penA mosaic allele XXXIV or other penA mosaic allele. It has been suggested that replacement of the methyl side chain of Ala501, which is located on the β3-β4 loop close to the KTG active site motif of PBP2, with the more bulky side chains of valine (A501V) or threonine (A501T), inhibits the binding of cefixime and ceftriaxone to PBP2 by clashing with their R1 substituents [25, 81] . The change of Ala501 to a proline (A501P) introduces secondary structure alterations that may result in even more dramatic changes, which is consistent with the much higher MICs conferred by the A501P alteration than the A501V and A501T alterations [25] . The crystal structure of PBP2 showing all amino acids currently verified to be involved in enhancing the MICs of ESCs is illustrated in Figure 3 .
Enhanced efflux & decreased influx of ESCs
Specific mutations in the promoter and/or coding sequence of mtrR, a transcriptional repressor of the mtrCDE operon, markedly increase the expression of the MtrC-MtrDMtrE efflux pump ('mtrR resistance determinant') that enhances the efflux of ESCs, particularly ceftriaxone, from the periplasmic space of the gonococcus and increases their MICs. The mtrR determinant is most often a single-base-pair (A) deletion in the 13-base pair (bp) inverted repeat of the promoter region, with G45D mutations (and other mutations) within the coding sequence of MtrR being less common [8, [23] [24] [25] [26] [27] [28] 31, 36, [39] [40] [41] 58, 68, 74, 78, 82, 86, [88] [89] [90] [91] . Other rare alterations that increase expression of the MtrCMtrD-MtrE efflux pump have been described: a 153-bp insertion sequence located between the mtrR/mtrC promoter and the mtrC gene [92] , and a C-to-T transition 120 bp upstream of the mtrC start codon (termed mtr120) that results in a consensus -10 element and a novel promoter for mtrCDE transcription [93] . mtrR mutations affect resistance in two ways: by directly increasing efflux of the ESC and by activating the penB resistance determinant, which has a resistant phenotype only when a mtrR mutation is present [86] . The penB resistance determinant encodes an altered porB1b allele with mutations that alter amino acid G101 (e.g., G101K) or both G101 and A102 (e.g., G101D/A102D) in the putative loop 3 of the PorB1b outer membrane porin. Acquisition of penB results in decreased influx of ESCs, particularly ceftriaxone, into the cell and increases their MICs [8, [23] [24] [25] [26] [27] [28] 31, 36, 58, 68, 74, 78, 82, 86, 89, 94, 95] . Synergy between the penA mosaic allele, mtrR, and penB has been reported in isolates with decreased susceptibility/resistance to ESCs, particularly ceftriaxone [23, 25, 86] . Interestingly, the great majority of cefixime resistance appears to be conferred by the penA mosaic allele, with mtrR and penB having only a minor effect on its MIC, whereas ceftriaxone resistance is nearly equally dependent upon penA and mtrR/penB. This result suggests that either cefixime does not readily diffuse into the periplasm through PorB or that such diffusion is not altered by the penB determinant. These data also suggest that cefixime is not an effective substrate for the MtrCMtrD-MtrE efflux pump. The net charge of cefixime (-2) differs from the net charge of penicillin (-1) and ceftriaxone (-1), which may affect the permeation properties of cefixime [86] .
Other current or possible future resistance determinants
Alterations in ponA (the ponA1 allele encoding PBP1 with an L421P mutation) and pilQ (encoding loss-of-function mutations in the pore-forming secretin PilQ protein of the type IV pili), both of which are involved in high-level penicillin resistance in strains containing penA alterations, mtrR and penB, do not appear to alter the ESC MICs in clinical isolates [8, 86, [96] [97] [98] . The ponA1 allele is present in most isolates with decreased susceptibility/ resistance to ESCs. However, this likely only reflects that these strains arose by transfer of penA mosaic alleles into pre-existing chromosomally mediated penicillin-resistant strains, which persist in high prevalence in the gonococcal population, despite the fact that penicillin was withdrawn from gonorrhea treatment regimens decades ago [86] . An unusual aspect of the ponA1 allele in penicillin resistance is that the introduction of ponA1 into a strain with penA, mtrR and penB resistance determinants has no effect on resistance, while reversion of ponA1 to wild-type in a penicillin-resistant strain decreases the MIC by twofold [96] . This may indicate epistasis or the presence of 'factor X', which is described in more detail below. pilQ2 (or any other pilQ loss-of-function mutation) has never been reported in clinical isolates, probably because it compromises type IV pilus formation and, thus, pathogenic potential [17, 97, 99] . Nevertheless, the effect(s) of ponA and/or pilQ polymorphisms in future ESC-resistant strains cannot be totally excluded.
While penA, mtrR and penB determinants markedly increase resistance, they do not confer donor levels of resistance to penicillin or ESCs (MICs ~three-to six-fold lower than donor strains). Attempts by many labs to transform strains already containing penA, mtrR and penB to donor MIC levels have been unsuccessful and, thus, the identity of this nontransformable penicillin and ESC resistance determinant (termed 'factor X') remains unknown [8, 23, 25, 78, 81, 86 ].
Fortunately, acquisition or development of an extended-spectrum β-lactamase (ESBL), which could degrade all ESCs, has not yet been reported in any gonococcal strain. However, in many strains the bla TEM-1 gene (encoding TEM-1 β-lactamase) appears to have evolved by one single nucleotide polymorphism (SNP) to bla TEM-135 and only one additional specific SNP could result in an ESBL [100] .
Public health actions to meet the large challenge of emergence of highlevel ceftriaxone-resistant & untreatable gonorrhea
In the age of easy international travel, the global trend of AMR in gonococci and resistance to ESCs, including treatment failures, demands a global approach to respond to the potential public health disaster that may occur with the emergence of untreatable gonorrhea. This is imperative, since gonococcal AMR data are lacking in many settings and the true global problem is, therefore, unknown. Accordingly, the WHO Global Gonococcal Antimicrobial Surveillance Programme (WHO Global GASP), initially established in the 1990s, was revisited and revamped in 2009, in close liaison with other existing AMR surveillance programs, in order to enable a coordinated global response. The WHO Global GASP network aims to recruit laboratories worldwide to: monitor quality-assured gonococcal AMR data (with particular attention to ESCs); provide support to establish gonococcal culture and AMR testing; inform public health authorities and treatment guidelines on trends in gonococcal AMR; optimize early detection of emerging resistance; and identify and verify treatment failures with ESCs [33] .
To facilitate the functioning of this WHO GASP network and engage the support of governments, the international community and appropriate donors, the WHO recently published the 'Global action plan to control the spread and impact of AMR in Neisseria gonorrhoeae' [33, 202] . This plan aims to enhance AMR surveillance worldwide through the WHO Global GASP, facilitate early detection and verification of resistance to recommended treatment (particularly ESCs) and combine these with a public health response to mitigate the impact of ESC-resistant gonococci on sexual and reproductive health morbidity. The WHO global action plan calls for a public health approach to the control of gonorrhea and the emergence of untreatable gonorrhea. The main components of the WHO global action plan are summarized in BOX 1. Several region-specific and national action/response plans to mitigate the spread of multidrug-resistant gonorrhea, which are also crucial for the global response, are under preparation or have been published. For example, the European CDC and the US CDC have launched public health response plans for EU/EEA countries [203] and the USA, respectively [204] .
Future options for treatment & prevention of gonorrhea
Even if the aforementioned action/response plans will be fully implemented, they would likely only delay, as opposed to halt, the inevitable international emergence and spread of ceftriaxone-resistant gonorrhea. Ultimately, new treatment strategies and novel antimicrobials are essential for the effective treatment of gonorrhea.
Increased doses of ESCs
Use of an increased dose of ceftriaxone has been implemented in most settings [1, 21, 26, 51, 59, 101, 102] . In some countries, such as Japan and China, ceftriaxone 1 g × 1 is recommended [59, 101, 103, 104] , and likely up to 2 g × 1 would be safe, based on the dosage used for treatment of community-acquired pneumonia. Cefixime is not licensed for doses higher than the currently used 400 mg × 1, due to frequent adverse gastrointestinal effects observed with a higher dose (800 mg × 1) [105] . Even so, increased doses of ceftriaxone will only provide a short-term solution. No currently available alternative cephalosporins, either injectable or oral, offer any advantage over ceftriaxone or cefixime in terms of efficacy and pharmokinetics/pharmacodynamics, and efficacy for pharyngeal infection is even less certain [14, 19, 62, 64] .
Dual antimicrobial therapy
An alternative approach to increasing the dose in ESC monotherapy is to use dual antimicrobial therapy, which also covers concurrent chlamydial infection, and recently this has been introduced in the UK [64], the whole of Europe [Bignell C, Unemo M. European guideline on the diagnosis and treatment of gonorrhoea in adults (2012), Submitted] and the USA [19, 106] . In the UK, ceftriaxone 500 mg × 1 (intramuscularly) plus azithromycin 1 g × 1 (orally) have been recommended since 2011 for uncomplicated anogenital gonorrhea [64] . The recommendation in the USA is ceftriaxone 250 mg × 1 (intramuscularly) plus azithromycin 1 g × 1 or doxycycline 100 mg (orally) twice-daily for 7 days [19, 106] . Synergy has been reported for ESCs and azithromycin in treatment, including for pharyngeal gonorrhea [107, 108] , and synergistic and/or additive effects can also be observed in vitro [UNEMO M, UNPUBLISHED DATA]. Dual antimicrobial therapy might also inhibit future development of gonococcal AMR. Accordingly, dual antimicrobial therapy appears effective, and, in fact, has been practiced in several years, primarily due to the frequent co-administration of azithromycin to gonorrhea patients for possible concomitant chlamydial infection. Unfortunately, susceptibility to ceftriaxone is decreasing, resistance to doxycycline is common and resistance to azithromycin has been selected rapidly in settings where it has been frequently used. In recent years, isolates with high-level resistance to azithromycin (MIC ≥256 μg/ml), due to an A2059G alteration (Escherichia coli numbering) in domain V in three or four of the four alleles of the 23S rRNA gene, have also been identified in several countries [109] [110] [111] [112] [113] . In the USA, a randomized clinical multicenter trial to evaluate the efficacy (and safety) of gentamicin (240 mg × 1 intramuscularly) plus azithromycin (2 g × 1 orally) and gemifloxacin (320 mg × 1 orally) plus azithromycin (2 g × 1 orally) for treatment of uncomplicated urogenital gonorrhea is also ongoing. In order to minimize the gastrointestinal side effects when administering 2 g × 1 of azithromycin, it would be valuable to have the new extended-release microsphere formulation of azithromycin available worldwide. Nevertheless, dual antimicrobial regimens, especially those with injections, might not be feasible and/or affordable in less-resourced settings, many of which suffer from the highest gonorrhea burden.
Antimicrobial monotherapy: any future options?
Effective antimicrobial monotherapy, or at least new antimicrobials for inclusion in a dual antimicrobial therapy regimens, appear essential for a long-term solution and from a global perspective. The aminocyclitol spectinomycin (2 g × 1 intramuscularly) is a theoretical option, and resistance to spectinomycin is also rare worldwide [1, 3, 7, 14, 18, 23 ]. Unfortunately, high-level resistance to spectinomycin rapidly emerged when it was widely used as a first-line option among US military personnel in Korea in the 1980s [114] . This resistance was due to only one SNP, C1192T (E. coli numbering), in the 16S rRNA gene. Nevertheless, the aminoglycoside gentamicin is now being considered for treatment of gonorrhea in several countries. Gentamicin (240 mg × 1 intramuscularly) has also been used as first-line treatment in Malawi since 1993 without any reported emergence of in vitro resistance [116, 117] , and the in vitro susceptibility in Europe appears high [118] . However, global susceptibility data remain sparse, appropriate correlates between MICs of gentamicin and treatment outcome are lacking (e.g., no microbiological resistance breakpoints exist), no data for treatment of pharyngeal or anorectal gonorrhea exist and it is not clear whether appropriate pharmacokinetic/pharmacodynamic targets for treatment of all cases of anogenital and pharyngeal gonorrhea can be reached. A recent meta-analysis also found that treatment with a single dose of gentamicin resulted in a pooled cure rate of only 91.5% (95% CI: 88.1-94.0%) [119] , which is substantially lower than the current criteria of ≥95% effectiveness for recommended treatment of gonorrhea. Furthermore, gentamicin has mainly been used in Malawi in syndromic management administered together with doxycycline and, thus, in a dual antimicrobial therapy regimen and not as a single antimicrobial therapy. Valuable information regarding the efficacy and safety of gentamicin in dual antimicrobial therapy of gonorrhea will soon be available from the ongoing clinical trial mentioned above.
The new fluoroketolide (antimicrobial class: macrolides), solithromycin (CEM-101), has recently been demonstrated to have high in vitro activity against gonococci, including ESCand multidrug-resistant isolates [120] . Solithromycin had an activity that was fourfold (MIC 50 ) to 32-fold (MIC 90 ) better than that of azithromycin and also appeared superior to most other antimicrobials tested [120] . The three binding sites for solithromycin (compared with two for other macrolides) on the bacterial ribosome probably result in this higher activity and are also expected to delay resistance development [120, 121] . Solithromycin is well absorbed orally, with high plasma levels, intracellular concentrations and tissue distribution, has a long post-antibiotic effect, and a 1.6 g × 1 oral dose appears well-tolerated [122] . Accordingly, solithromycin might be appropriate for single antimicrobial therapy, especially of infections by ESC-resistant strains, and particularly in dual antimicrobial therapy of gonorrhea, which likely would further delay resistance development. Furthermore, the susceptibility of Chlamydia trachomatis [123] and Mycoplasma genitalium [124] to solithromycin indicates that it may be an option for treatment of several sexually transmitted infections, including management of urethral and vaginal discharge syndromes. Nevertheless, gonococcal isolates with ribosomal mutations resulting in high-level resistance to azithromycin (MIC ≥256 μg/ml) have MICs of 4-32 μg/ml for solithromycin, which presumably reflects resistance [120] . In the USA, a minor open-label, single-center study to evaluate the efficacy and safety of an oral 1.2 g × 1 dose of solithromycin for treatment of uncomplicated urogenital gonorrhea is ongoing.
The in vitro activity of ertapenem (parenteral 1-β-methyl-carbapenem) against N. gonorrhoeae also appears to be high [125] . Ertapenem did not have any in vitro advantage over ceftriaxone for isolates that were susceptible or intermediate-susceptible to ceftriaxone. Nevertheless, for isolates with resistance to ceftriaxone (MIC = 0.5-4 μg/ml), the corresponding MICs of ertapenem remained low (0.016-0.064 μg/ml) [125] . Ertapenem was also highly active against multidrug-resistant isolates [125] , as well as being safe, welltolerated and effective against urinary tract infections [126, 127] . Thus, ertapenem might be a treatment option for gonorrhea, particularly for the currently identified ESC-resistant cases and especially in dual antimicrobial therapy. However, despite the observation that ceftriaxone-resistant isolates (n = 4) had relatively low ertapenem MICs, ESC resistance determinants, such as mosaic penA alleles, mtrR and penB, increase the MIC of ertapenem [125] . The decrease in susceptibility to ertapenem indicates that gonococci have already acquired initial determinants for ertapenem resistance, and the eventual remodeling of PBP2 to specifically exclude ertapenem, which would work synergistically with the existing resistance determinants, seems likely. Due to these facts and the pharmacokinetic/ pharmacodynamic considerations of ertapenem, it may not be suitable for future gonorrhea treatment. Finally, the future possibility of acquisition of a carbapenemase or a TEM-1 β-lactamase that evolves into an ESBL to degrade ertapenem cannot be excluded, especially when the bla TEM-1 gene appears to be evolving [100] .
Tigecycline, a broad-spectrum parenteral glycylcycline, is a tetracycline derivative that has shown high in vitro activity against gonococci, including tetracycline-resistant isolates [3, 14, 128] . However, tigecycline has not been examined against multidrug-resistant gonococci (including ESC-resistant isolates) or evaluated in vivo for treatment of gonorrhea.
Furthermore, because tigecycline is mainly eliminated into the bile and a relatively small proportion of the administered drug is excreted unchanged in the urine, the use of tigecycline for treatment of urinary tract infections has been debated [129] [130] [131] .
Evaluation of novel treatment options
All novel single or dual antimicrobial treatment regimens for gonorrhea ideally require upto-date and comprehensive in vitro and in vivo evaluation, including appropriately designed, randomized and controlled treatment studies evaluating parameters such as efficacy, safety, toxicity, cost, optimal dose and pharmacokinetic/pharmacodynamics data for genital and extragenital (especially pharyngeal) gonorrhea. Furthermore, knowledge regarding current and future genetic resistance determinants (in vitro selected and in vivo emerged) for these antimicrobials (both in gonococci and bystander organisms when treating gonorrhea) clear correlates between genetic and phenotypic laboratory parameters, and clinical treatment outcomes, would be exceedingly valuable.
Pipeline for future therapeutic options
There are no novel antimicrobial options for the effective treatment of gonorrhea in late development [1, 11, 14, 17, 19, 23] . N. gonorrhoeae has rapidly developed resistance to all antimicrobials introduced for first-line therapy during the last 70-80 years [1, 11, 17] . Given the fear of emergence of untreatable gonorrhea, it is essential to think 'outside the box' and investigate new targets, compounds and strategies for treatment, and, ideally, to develop an effective gonococcal vaccine.
Pleuromutilin antimicrobials are potent inhibitors of bacterial protein synthesis that bind to novel sites on bacterial ribosome, which are active against gonococci and suitable for systemic use [132, 133] . Both the pleuromutilins and novel inhibitors of bacterial topoisomerases targeting regions different from the fluoroquinolone-binding site [134] may deserve attention for potential antimicrobial treatment of gonorrhea.
Other novel compounds that are under development or could be developed include: speciesspecific FabI inhibitors with activity against gonococci, such as MUT056399 [135] ; inhibitors of efflux pumps that increase the susceptibility to certain antimicrobials, innate host defense and toxic metabolites [136] ; LpxC inhibitors having potent antigonococcal activity [137] ; molecules mimicking host defensins; and host defense peptides such as LL-37 (multifunctional cathelicidin peptide) [138] .
Prospects for a gonococcal vaccine
The search for a gonococcal vaccine is complicated, since even a natural uncomplicated gonococcal infection results only in a mostly local, relatively low and non-persistent immune response that provides little to no protection to reinfection even with an identical strain. To date, no vaccine has been developed, despite the fact that whole organisms, numerous purified gonococcal components and recombinant proteins have been tested. The major obstacles for developing a vaccine have been: gonococcal production of nonbactericidal antibodies (e.g., against Rmp) that block bactericidal antibodies (e.g., against PorB and LOS); sialylation of gonococci and subsequent binding of alternative complement regulator factor H; potential elicitation of gonococcal IL-17 responses that suppress Th1/Th2 adaptive immune responses to natural infection; high antigenic heterogeneity in gonococci (including antigenic variability and phase variation of surface structures, e.g., pili, Opa proteins and LOS); general lack of correlates for immune protection; and lack of an ideal animal model for this obligate human pathogen [139] [140] [141] . Nevertheless, several recent advances may enable future gonococcal vaccine research: development of transgenic mouse models expressing human genes required for gonococcal infection; better definition of the course of natural infection through the use of experimental infection in male volunteers [142] ; enhanced knowledge regarding development of polyvalent vaccines (which might be required for gonorrhea) gained from the reverse vaccinology technology used for meningococcal vaccines [143] ; modern molecular biology, including genome sequencing for the identification of novel single or multiple vaccine candidate antigens; recombinant protein vaccines; discoveries in genital mucosal immunology; and intranasal immunization for increased local mucosal immune responses [140, 141, 144] . A vaccine that generates a partial immunity, which might not inhibit uncomplicated gonorrhea but eradicates the severe complications of the disease, would still be valuable.
Future perspective
It appears inevitable that ceftriaxone-resistant gonococcal strains with retained resistance determinants to previously recommended antimicrobials will spread internationally, possibly heralding an era of untreatable gonorrhea. This would be an exceedingly serious public health problem that would result in substantial morbidity from the severe sequelae caused by untreated gonorrhea worldwide. Accordingly, timely, decisive, multidisciplinary and multicomponent public health actions are essential worldwide. Strict implementation of the WHO global action plan [33, 202] and region-specific action/response plans [203, 204] is crucial. The WHO Global GASP, in close liaison with other regional/national GASPs, needs to: substantially enhance gonococcal AMR surveillance worldwide, with a focus on ESCs; inform public health authorities about national and regional treatment guidelines; optimize early detection of emerging AMR; and support the early identification, verification and follow-up (including tracing of sexual contacts) of treatment failures [33, 202, 207] .
Currently, quality-assured surveillance of gonococcal AMR and treatment failures remains sporadic, limited or lacking in many regions globally [1, 12, 20, [59] [60] [61] . The limited use of gonococcal culture and AMR testing worldwide is mostly the result of using syndromic management and microscopy for diagnosis in less-resourced settings, and nucleic acid amplification tests in more resourced settings. It is crucial to culture more isolates, examine AMR, and identify specific ESC resistance determinants, to facilitate AMR surveillance and develop sensitive and specific genetic ESC resistance testing assays. The recently revised WHO standards [207] describe appropriate sampling, transportation and culture of gonococcal isolates, quality-assured AMR testing using WHO gonococcal reference strains [82] and methods to increase the sampling for AMR testing, such as using targeted culture of N. gonorrhoeae microscopy and/or nucleic acid amplification test-positive samples.
Furthermore, well-established GASPs should increase the number and representativeness of gonococcal isolates tested (most GASPs include mainly isolates from symptomatic male urethritis from relatively few clinics per country) and epidemiological data collected to prevent emergence of AMR in overlooked populations. Finally, it is also crucial to optimize and, as much as feasible, harmonize the methods, interpretative criteria (breakpoints) and internal and external quality assurance used globally. This is essential to be able to compare validated and quality assured AMR data internationally.
The WHO global action plan [33, 202] additionally stresses the importance of combining enhanced surveillance of AMR and treatment failures with a public health response to mitigate the emergence, spread and impact of gonorrhea, particularly ESC-resistant gonococci. Accordingly, crucial actions also include: encouraging increased awareness of gonococcal AMR; correct use of antimicrobials; effective early prevention (e.g., information, counseling and safe sex), diagnosis and management of gonorrhea; effective drug regulation and prescription policies (using only ideal antimicrobials of appropriate quality and optimized doses); development of molecular methods for detecting and monitoring ESC resistance; and, most importantly, research (basic science, in vitro and in vivo studies) to identify new effective treatment strategies, novel antimicrobials and ideally a vaccine (BOX 1) [1, 33, 202 ]. An increased focus on preventing, diagnosing and treating pharyngeal gonorrhea, with special attention to pharmacokinetic/pharmacodynamic considerations, is also crucial. This includes increasing the sampling of pharyngeal specimens and promoting condom use when practicing oral sex. Pharyngeal infections are harder to treat than urogenital infection, they are relatively common and represent an asymptomatic reservoir for infection and emergence of resistance [1, 3, 14, 17, 19, 20, [34] [35] [36] [62] [63] [64] . Finally, widespread implementation of test-of-cure is important to identify treatment failures and reinfection -particularly, but not only, for pharyngeal infections.
Genetic methods for detecting and monitoring ESC resistance would be extremely valuable, and some methods identifying different or specific penA mosaic alleles or other chromosomal AMR determinants have been developed [71, [145] [146] [147] [148] [149] . Unfortunately, the currently available penA mosaic PCR detection methods have suboptimal sensitivity and specificity in their predictive power of ESC resistance, in general, and are suboptimal for clinical specimens. The reasons for this are that the MICs of ESCs for strains with different mosaic and Ala501-altered non-mosaic penA alleles vary markedly, making it crucial to sequence the penA gene (rather than simply using some penA mosaic PCR that detects all the different types of penA mosaic alleles or only a specific penA mosaic allele) and identify other AMR determinants in these isolates. Additionally, most penA mosaic sequences originate in commensal Neisseria species, making it hard to determine ESC resistance particularly in extragenital specimen such as those taken from the pharynx [1, 8, 23, 25, 72, 77, 80, 83, 84] . Initially, statistical associations between specific amino acid alterations and elevated ESC MICs are exceedingly important to identify. However, this approach also requires subsequent verification of the amino acid alterations (including their possible epistasis) that enhance the MICs of ESCs by transformation of site-directed penA mutants into isogenic strain backgrounds. It is also important to agree on the nomenclature of gonococcal penA alleles (or PBP2 alleles), which includes generating an internationally accessible database containing the full-length sequence, the name of the allele, and, ideally, appropriate additional microbiological, genetic and epidemiologic data.
Nevertheless, accumulating knowledge regarding ESC resistance determinants combined with recent advances in genome sequencing, nanotechnology and other molecular approaches might enable sensitive and specific genetic ESC resistance assays (ideally at point-of-care [POC]), as well as genetic POC diagnostic tests, which might substantially improve early detection, particularly in less resourced settings worldwide. These POC tests should be able to detect not only ESC resistance/susceptibility, but also resistance/ susceptibility to many of the antimicrobials previously recommended for treatment of gonorrhea, and the results should be available in a timely manner and used not only for gonococcal AMR surveillance, but also to direct the treatment of the individual patient. Nevertheless, it is essential to retain culture and phenotypic AMR testing methods, that is, to be able to detect novel resistance and inform the design and redesign of the genetic AMR assays. New sequencing technologies can also substantially improve the molecular epidemiological typing of gonococci [150] , elucidate the dynamics of the national and international spread of AMR gonococcal clones (microepidemiology and microepidemiology), and detail the evolution of successful AMR gonococcal clones and their AMR determinants, including prediction of emergence.
Unfortunately, the aforementioned action/response plans will only delay and limit, but not halt, the inevitable spread of ceftriaxone resistance globally. Therefore, it is essential to develop novel treatment strategies and antimicrobials in a timely manner. Using an increased dose of ceftriaxone will provide a short-term solution, but introduction of dual antimicrobial therapy (currently ceftriaxone and azithromycin) covering concurrent chlamydial infection [19, 64, 106] , is recommended for most settings and, hopefully, will also inhibit future development of gonococcal AMR. Additional research is needed regarding which antimicrobials (and at what dosages) to combine, and to document efficacy, side effects, pharmacokinetic/pharmacodynamic parameters, resistance development (in gonococci and bystander organisms), in vitro methods for synergy testing and microbiological resistance breakpoints. Unfortunately, gonococcal strains with decreased susceptibility/resistance to ceftriaxone with concomitant resistance to both azithromycin and doxycycline are already circulating globally, making it crucial to develop new alternatives for dual antimicrobial therapy. Furthermore, dual antimicrobial therapy, especially with injectable antimicrobials, might not be feasible and/or affordable in less-resourced settings (with a substantial gonorrhea burden) and, thus, may not significantly mitigate AMR emergence and global spread. Accordingly, from a global perspective, an antimicrobial monotherapy appears essential [1, 17, 23, 25] , however, currently there are no promising options [1, 3, 11, 14, 19, 23, 25] . Spectinomycin is a theoretical option, but it is not available in many countries and resistance can be rapidly selected [1, 3, 14, 114, 115] . Nevertheless, it would be valuable to have spectinomycin available to treat emergent ESC-resistant cases and possibly for inclusion in a dual antimicrobial treatment regimen, which could inhibit the development of resistance and effectively treat gonorrhoea, including pharyngeal infection. Although new antimicrobials (i.e., gentamicin [116] [117] [118] [119] , solithromycin [120] and ertapenem [125] ) have been suggested for treatment, comprehensive and quality-assured in vitro and/or in vivo evaluation of these antimicrobials remains lacking, and none appear ideal for single antimicrobial therapy. N. gonorrhoeae has rapidly developed resistance to all antimicrobials introduced for first-line therapy during the last 70-80 years [1, 11, 17] and, thus, it is essential to develop new antimicrobials, investigate novel non-antimicrobial targets and define the mechanisms of action for more sustainable treatment. A gonococcal vaccine would be especially useful, however progress in this area remains minimal.
In conclusion, an era of untreatable gonorrhea may be approaching, which represents a serious public health problem. It is crucial to implement action/response plans at global and national levels, focus research and funding on enhanced surveillance of gonococcal AMR (phenotypic and genetic) and treatment failures, and to improve the prevention, early diagnosis and effective treatment of gonorrhea. Novel effective treatment strategies, new antimicrobials (or other compounds) and, ideally, a gonococcal vaccine should be developed. has been demonstrated to be involved in penicillin resistance, but not yet in resistance to extended-spectrum cephalosporins. The structure of PBP2 is from Neisseria gonorrhoeae.
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